Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2019-11-07. The firm is focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer.
Galera Therapeutics Inc 最大收入來源為 ADI Global Distribution,在最近的收益報告中收入為 4,197,000,000。就地區而言,United States 是 Galera Therapeutics Inc 的主要市場,收入為 5,232,000,000。